Evidence map›Paper›PMID 35158801›Full record

ArticleCancers2022

Exploration of Extracellular Vesicle miRNAs, Targeted mRNAs and Pathways in Prostate Cancer: Relation to Disease Status and Progression.

Maija Puhka, Lisse Thierens, Daniel Nicorici, Tarja Forsman, Tuomas Mirtti, Taija Af Hällström, Elina Serkkola, Antti Rannikko

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Maija PuhkaHiPrep and EV Core, Institute for Molecular Medicine Finland FIMM, University of Helsinki, 00290 Helsinki, Finland.ORCID 0000-0002-6445-1017
Lisse ThierensHiPrep and EV Core, Institute for Molecular Medicine Finland FIMM, University of Helsinki, 00290 Helsinki, Finland.
Daniel NicoriciOrion Pharma, Orion Corporation, 02200 Espoo, Finland.
Tarja ForsmanOrion Pharma, Orion Corporation, 02200 Espoo, Finland.
Tuomas MirttiDepartment of Pathology, HUS Diagnostic Centre, Helsinki University Hospital, 00290 Helsinki, Finland.ORCID 0000-0003-0455-9891
Taija Af HällströmAstraZeneca, 02600 Espoo, Finland.
Elina SerkkolaOrion Pharma, Orion Corporation, 02200 Espoo, Finland.
Antti RannikkoResearch Program in Systems Oncology, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland.
University of Helsinki · FIOrion Corporation (Finland) · FIAstraZeneca (Finland) · FI

Funding

Tekes 3986/31/2013
6 · The paper itself

Abstract

backgroundProstate cancer (PCa) lacks non-invasive specific biomarkers for aggressive disease. We studied the potential of urinary extracellular vesicles (uEV) as a liquid PCa biopsy by focusing on the micro RNA (miRNA) cargo, target messenger RNA (mRNA) and pathway analysis.

methodsWe subjected uEV samples from 31 PCa patients (pre-prostatectomy) to miRNA sequencing and matched uEV and plasma EV (pEV) from three PCa patients to mRNA sequencing. EV quality control was performed by electron microscopy, Western blotting and particle and RNA analysis. We compared miRNA expression based on PCa status (Gleason Score) and progression (post-prostatectomy follow-up) and confirmed selected miRNAs by quantitative PCR. Expression of target mRNAs was mapped in matched EV.

resultsQuality control showed typical small uEV, pEV, RNA and EV-protein marker enriched samples. Comparisons between PCa groups revealed mostly unique differentially expressed miRNAs. However, they targeted comprehensive and largely overlapping sets of cancer and progression-associated signalling, resistance, hormonal and immune pathways. Quantitative PCR confirmed changes in miR-892a (Gleason Score 7 vs. ≥8), miR-223-3p (progression vs. no progression) and miR-146a-5p (both comparisons). Their target mRNAs were expressed widely in PCa EV.

conclusionsPCa status and progression-linked RNAs in uEV are worth exploration in large personalized medicine trials.

Indexed as

exosomesextracellular vesiclesmessenger RNAmicro RNApathwayprogressionprostate cancersequencing

Identifiers

PMID35158801
PMCPMC8833493
OpenAlexW4205849232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.